A B S T R A C T Both acute and chronic cellular inflammatory reactions were suppressed in rats bearing malignant tumors. Inhibition of the acute inflammatory reactions was demonstrated in immune complex-induced vasculitis and in the accumulation of leukocytes in subcutaneously implanted polyvinyl sponges. Suppression of chronic inflammatory reactions was demonstrated in delayed type hypersensitivity skin reactions. In spite of these suppressed reactions, dermal reactivity to vasopermeability mediators was not diminished. Neither serum complement levels nor numbers of circulating leukocytes were depressed in animals with tumors. Suppression of inflammatory reactions was paralleled by a leukotactic defect which involved both neutrophils and monocytes. This defect could be ascribed to an abnormality in the serum that rendered both cell types leukotactically defective.
INTRODUCTION
Depression of cellular inflammatory responses in patients with malignancies has been well documented (1, 2) . However, to what extent these abnormalities are responsible for compromised ability of the host to control malignant tumors is not known. Many of the immunologic mechanisms that seem related to the control of tumor growth require the mobilization of inflammatory cells at sites of tumors. Cell-mediated immune reactions are thought to lead to the accumulation, and perhaps the activation, of a variety of inflammatory cells, particularly basophils, lymphocytes, and macrophages, the last cell type seeming to be a major participant in tumor cell destruction (3) .
It is well known that adenocarcinomas of the breast which incite a mononuclear cell response (monocytes and lymphocytes) carry a considerably better prognosis than those adenocarcinomas that fail to incite inflammatory cell reactions (4) . In patients with a variety of different types of solid tumors, impaired cell-mediated Received for publication 24 November 1978 and in revised form 1 February 1979. 302 immunity has often been associated with recurrence and(or) progression of the malignancy, whereas vigorous cellular immune reactions (whether occurring spontaneously or induced by immunotherapeutic means) have been associated with good prognosis (5) .
It is possible that depressed delayed type hypersensitivity responses in tumor-bearing animals and humans are not solely the result of suppressed immune responsiveness, but also, perhaps, the result of a broad defect in the expression of inflammatory responses. Inflammation resulting from agents (such as croton oil) that do not demonstrably require immunological mechanisms for induction of inflammation has been reported to be depressed in cancer patients who are also unresponsive to the contact sensitizing agent 2,4-dinitrochlorobenzene (6) . It is possible that failure to respond to the hapten could be because of defective inflammatory responsiveness rather than a suppressed cellular immune system.
In Walker tumor-bearing rats an inactivator ofchemotactic factors has been found in both the homogenates of tumor cells and in the ascites fluids bathing the tumor cells (7) . It was postulated that such an inactivator of chemotactic mediators might be responsible for the observations that the inflammatory response to a cotton thread implanted in vivo into a bed of connective tissue containing transplantable tumor cells is markedly depressed as compared to the thread in adjacent normal connective tissue (8) . A similar suggestion has recently been made to explain the suppressed inflammatory responses in mice at sites of injected malignant cells (9) .
In patients with Hodgkins disease a serum factor with chemotactic inactivator activity has been described (10) . It was suggested that the anergic state in Hodgkins disease was not restricted to an abnormality in the accumulation of monocytes and lymphocytes, but was associated with an abnormality involving all inflammatory cells under leukotactic control.
Other inhibitors of leukotaxis have also been described in humans and in animals with malignant tumors. A cell-directed inhibitor of leukotaxis has been described in the sera ofnearly two-thirds ofpatients with carcinoma or sarcoma (11) . Cell-directed inhibitor reversibly inhibits chemotactic responsiveness of neutrophils as well as monocytes. Phagocytic uptake of radiolabeled immune precipitates (antibody-antigen complexes) by neutrophils is also suppressed by cell-directed inhibitor.
Recently, defective monocyte chemotactic function has been reported in patients with malignant tumors. This defect disappears after successful surgical treatment of the tumor.' In studies with mice, it has been reported that the presence oftumor impairs macrophage function and suppresses inflammatory responses of the host (12) . Extracts of mouse neoplasm were shown to possess a low molecular weight factor capable of inhibiting macrophage chemotaxis in vitro and when injected into normal mice, before injection of a transplantable tumor, resulted in accelerated tumor growth, presumably because of a compromise in host defense mechanism.
In this study a defect in mobilization of neutrophils in acute inflammatory reactions was found in rats with either Walker or Novikoff tumors. In addition, defective delayed type hypersensitivity responses were noted, suggesting that the anergic state in tumor-bearing animals is not limited to monocyte-lymphocyte dysfunction, but represents a broader defect in the effector limb of the inflammatory response.
METHODS
Tumors. Walker carcinosarcoma and Novikoff hepatoma cells were maintained in inbred Lewis rats (obtained from Microbiological Associates, Walkersville, Md.). Tumors were carried either in the ascites form or in the solid form, as subcutaneous tumors in extremities. Between 1-2 x 107 tumor cells were injected for each passage. Most of the studies to be reported employed tumors maintained in the subcutaneous (solid) form.
Reversed passive Arthus reaction. Reversed passive Arthus reactions were induced in 200-to 225-g Lewis rats by the intravenous injection of 10 mg of bovine serum albumin (BSA)2 and the intradermal injection of 100 ,ug precipitating antibody N to BSA (13) . The antibody preparation was obtained as the IgG fraction isolated from hyperimmune rabbit sera. The Arthus-induced premeability changes were measured by the intravenous injection of homologous rat IgG isolated from normal rat serum and radiolabeled with 125I (14) . Each animal received an injection of 1251-IgG (_20 Ag containing 105 cpm) together with the BSA. Permeability was assessed by measuring the leakage of radiolabeled rat 1251-IgG into skin sites of' animals bearing either Walker or Novikoff tumors. 3Y2 h after injection of the immune reactants, skin sites were removed and the amount of radioactivity in each site measured. The data were expressed as counts per skin site. This radioactivity was then related (by ratio) to the number of radioactive (19) . Filters of 5.0 ,um pore size (Millipore Corp., Bedford, Mass.) were used and the chemotactic activity was quantitated by counting the number of cells that had migrated to various distances from the surface monolayer in five randomly selected fields (x 140 magnification). Cells were counted at each consecutive 10 ,um depth beneath the monolayer and a leukotactic index was calculated in a manner similar to that described previously (11) . Briefly, the total number of cells at each depth of the filter is multiplied by that distance. These products are then summed and divided by the total number of cells counted. The division yields the chemotactic index.
Various serum samples from either normal or tumor-bearing rats were tested for their effects on rat neutrophil chemotaxis by incubating various volutmes (10-100 ,ul) of the serum with 3.0 x 106 neutrophils (obtained from normal donors) in 0.5-ml volumes at 37°C for 20 min. The cell suspensions were then brought to 1.0-ml volumes with medium 199 and tested in chemotactic chambers, using partially purified C5a (= 1 ,ug/ml) that had been isolated from complement-activated human serum (19) .
In experiments involving macrophage chemotaxis, 3 ml of a 12% casein solution was injected intraperitoneally into Lewis rats to induce a mononuclear cell exudate. 3 
d after the casein
Depressed Inflammation in Cancer injection, the peritoneal exudate cells were harvested, washed, and placed on a Ficoll-Hypaque gradient (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) to obtain a pure cell suspension (>90% monocytes/macrophages). The cells were then washed two times with medium 199 and tested in Boyden chemotactic chambers using 8.0-,um micropore filters and partially purified C5a. Macrophage leukotaxis was assessed by counting the total number of macrophages migrating in five different oil-immersion fields.
Delayed type hypersensitivity reactions. Young adult male Lewis rats (200-225 g) were injected in one hind footpad with 0.1 ml of BSA in complete Freund's adjuvant which had been prepared with 1 ml (75 mg) BSA and 5.0 ml complete Freund's adjuvant according to methods previously described (20) .
Intradermal skin challenges with 8 ,ug BSA were performed on the shaved flanks between 10 and 18 d after immunization. Skin reactions were observed routinely at 3, 6, 15, 18, 24, and 36 h after challenge. The reactions beginning at 6-8 h reached a maximum intensity between 15 and 18 h and persisted for 24-36 h. The average diameters (in millimeters) of induration were determined when the reactions reached their maximum intensity (at 15-18 h). Hemorrhage was not evident grossly in the skin sites. Histological examination of fixed and stained tumor sections revealed the expected diffuse infiltrates of mononuclear cells 16 h after injection of antigen. In animals skin tested a second time (17 d after immunization) the intradermal injection was administered to a flank area contralateral to the prior skin test area.
RESULTS
Depressed Arthus reaction in tumor-bearing rats As reflected by measurements of vascular damage, data in Fig. 1 Table I indicate that the total hemolytic complement activity of sera from tumor-bearing rats was not depressed; ifanything, the values were slightly elevated. These data would suggest that the defective reversed passive Arthus reactions in tumor-bearing rats are neither associated with reduced amounts ofavailable serum complement nor with depressed numbers of circulating leukocytes.
Cutaneous responsiveness of permeability factors in tumor-bearing rats As indicated by the data in Table II , the permeability changes in dermal sites induced by various permeability mediators were not depressed in rats bearing Walker or Novikoff tumors. Rats with Walker tumors were equally reactive to serotonin, bradykinin, and histamine when compared with nontumor-bearing control rats. In animals with Novikoff tumors, the reactivity to the permeability factors serotonin and histamine was _2.5 times greater than the reactivity found in normal rats or animals with the Walker tumor. In contrast, reactivity of Novikoff tumor-bearing rats to bradykinin was not altered (Table II) . Reasons for the increased reactivity in animals with Novikofftumors to two of the three permeability agents (and also to saline injection) are not known. These data would suggest that the defect in the inflammatory response of rats with tumors is not due to a diminished reactivity of vessels to vasopermeability mediators.
Defective accumulation of neutrophils in vivo
To quantitate the ability of leukocytes from tumorbearing rats to respond in vivo to chemotactic stimuli, polyvinyl sponges presoaked either in Hanks' salt solution or in a solution of bacterial chemotactic factor were implanted subcutaneously in the flanks of normal and tumor-bearing rats. In experiments A and B (Table III) the results indicate that, regardless of whether or not sponges had been presoaked in chemotactic factor, twice the number of leukocytes accumulated in sponges implanted in normal animals compared with the number of leukocytes accumulating in sponges implanted in tumor-bearing animals. The differences in leukocyte accumulation in animals with and without tumor were found to be highly significant (P s 0.001 for experiment A and P c 0.05 for experiment B). In all cases >90% of cells were neutrophils, the remainder being monocytes.
It has been shown elsewhere that leukocyte migration into polyvinyl sponges containing only Hanks' salt solution is dependent on the availability of serum complement (18) . The difference between leukocyte content in control sponges containing only Hanks' solution in normal and tumor-bearing animals probably cannot be attributed to differences in serum comple- Delayed type hypersensitivity skin reactions were studied before and during the tumor-bearing period and, also, sequentially in tumor-free rats. During the 6-d interval, skin reactivity in control (nontumor bearing) rats remained unaltered (Table IV) Table V indicate that neutrophils from tumor-bearing animals were significantly less responsive to chemotactic stimuli when compared to neutrophils from normal animals. The average reduction was 25%, which represents a highly significant fall in leukotactic responsiveness (10 whereas the mean number of macrophages migrating into the filter from 10 different tumor-bearing rats was 16.7+2.2, an average difference of 44%. These data indicate that leukotactic responsiveness of macrophages is significantly suppressed in tumor-bearing rats (P ' 0.001).
Chemotactic inhibitory effect of serum from tumor-bearing rats
To determine if the defect in leukotactic responsiveness could be attributed to a serum abnormality, neutrophils from glycogen-induced peritoneal exudates of nontumor-bearing rats were tested for their ability to migrate chemotactically in the presence ofeither normal serum or serum from rats with solid Walker tumors. Normal serum was obtained from rats 2 d before intramuscular injection of 107 Walker tumor cells and frozen at -70'C. 2 wk later serum was obtained from the same animals. The 50-/l serum samples were incubated with 3 x 106 rat leukocytes at 37'C for 20 min before testing in chemotactic chambers. Data shown in Table  VII indicate that the presence of serum from seven normal rats bled over a 16-d interval does not alter the average leukotactic index. In contrast, sera from eight rats obtained before and 16 d after intramuscular implantation oftumor clearly showed that tumor presence was related to a serum-associated depression of the leukotactic response. In seven of the eight animals the index fell between 19 and 49%, with an average reduction of 30% (Table VII) . The data in Tables V and   VII suggest that the leukotactic defect in tumor-bearing rats is an acquired leukocyte abnormality that may be related to a serum factor.
The possibility was considered that blood-derived neutrophils might reflect a different susceptibility to inhibitory effects of serum from tumor-bearing animals when compared with the exudate neutrophils described in Table VII . Accordingly, neutrophils were obtained from normal rat blood (which contained 10 U heparin! ml) after dextran sedimentation of the erythrocytes. Aliquots of the neutrophils were then suspended in five different sera obtained from normal rats and five rats with Walker tumors. The protocol was similar to that described in Table VII . When compared with responses in normal serum, the same cells in serum from tumor-bearing rats induced the following degree of chemotactic inhibition: 66, 76, 56, 66, and 31%, with a mean inhibition of 58.8+11.5. These data would suggest blood derived neutrophils show a similar degree of susecptibility to chemotactic inhibition as do the cells obtained from the peritoneal exudates.
Serum dose-response effect on leukotaxis Dose-response experiments were performed using sera from animals before and after tumor implantation. Neutrophils (peritoneal exudate) from a normal donor were used as indicator cells whereas the C5 fragment served as the attractant. As expected, with sera which had been obtained from three normal donors (Fig. 2) before tumor passage, the chemotactic response progressively improved in direct proportion to the amount of serum in the cell suspension. When the same cells were tested under the same conditions, but now with sera which had been obtained from the same animals 16 d after tumor passage, significant differences were noted in the effects of the sera in chemotaxis. The response of the cells in the presence of tumor-bearing sera (Fig. 2) were, in general, between 25 and 50% depressed when compared with the sera obtained before passage. The dose responses do not permit a distinction between the presence of a chemotactic inhibitor vs. the lack of a chemotactic-enhancing factor.
DISCUSSION
The data presented in this report suggest that in animals with malignant tumors there is a broad defect in expression of the inflammatory response, involving both acute and chronic cellular inflammatory reactions (Fig. 1 (Table III) . Correlated with tions that normal lymphocytes sensitized to specific antigen also fail to transfer delayed hypersensitivity when transferred into cancer patients, whereas in recipient patients without malignancies, this transfer is effective (22) . Recent evidence that cancer patients fail to respond with inflammatory cells to nonspecific stimuli (croton oil) or to skin-sensitizing agents (dinitrochlorobenzene) suggests that there may be a generalized defect in the mobilization of inflammatory cells rather than defects that are restricted to T lymphocytes (6) .
Several earlier studies support this hypothesis. Baum reported that polymorphonuclear leukocyte chemotactic responsiveness was impaired in patients with carcinoma and that this was indicative of poor prognosis. In contrast, in those patients with malignancies and whose neutrophil leukotactic responsiveness remained normal, this was indicative of a good prognosis (23) .
In some studies an acquired defect in monocyte chemotactic responsiveness has been demonstrated in patients with malignancies.2 The suppressed monocyte leukotactic responsiveness could not be corrected by washing the cells and resuspending them in normal human serum. Only after surgical removal of the tumor did in vitro monocyte leukotactic responsiveness return to normal levels. In an extension of these studies, a factor of low molecular weight was extracted from tumor cells but not from companion normal cells. This factor impaired the in vitro chemotactic responsiveness of moncytes. When injected in vivo into tumor-bearing animals, this factor caused an acceleration in the growth of the tumor, presumably because of an effect on the host monocytes. An entirely different type of product from tumor cells with inhibitory effects on the chemotactic system is the chemotactic factor inactivator which has been found in ascitic fluids associated with malignant tumors of rats (7) . Thus, at least two different inhibitors of the chemotactic system are derived from malignant cells. The studies undertaken in the present report indicate that a cell-associated defect in chemotaxis exists and that this can at least in part be explained by a serum-associated inhibitor. The fact that leukocytes from tumor-bearing rats are chemotactically defective, even after they are washed and resuspended in normal serum, and the ability to transfer the inhibition in vitro with serum, would point to a cell directed inhibitor rather than a chemotactic factor inactivator. The serum inhibitor in the present report is not further defined. Whether it is similar to the cell-directed inhibitor found in the serum of humans with malignant tumors or similar to the cell directed inhibitor extracted from experimental tumors is not known.
The observations presented in this report suggest that the inflammatory defect in tumor-bearing animals is not merely a defect in immune recognition but an expression of a generalized defect in the effector limb of the inflammatory response. This hypothesis is supported by the data presented in this paper describing a broad range of inflammatory defects.
These studies do not conflict with the established fact that immune reactivity in cancer patients can itself be defective. Lymphocyte unresponsiveness to antigenic challenge in vivo can be because of either an afferent limb or efferent limb dysfunction. The data presented in this study suggest that failure to mobilize cellular inflammatory reactions in tumor-bearing rats may be due not only to a defect in the afferent recognition limb of inflammation but to a broad range defect in the effector limb ofthe inflammatory response. This is an important consideration, since there is good experimental evidence that neutrophils, basophils, lymphocytes and macrophages each have, under certain experimental conditions, important cytotoxic or cytocidal activities for tumor cells (24) (25) (26) (27) . If either the afferent or efferent limb of immune system is rendered defective in an individual with a malignant tumor and (or) the ability to mobilize inflammatory cells is defective, that individual has effectively lost virtually all host defense mechanisms for combating the tumor. As such, the observations in this paper assume broad significance.
